Annual Report to the Nation on the Status of Cancer, 1975-2012, featuring the increasing incidence of liver cancer

Cancer

Volumn 122, Issue 9, 2016, Pages 1312-1337

  Ryerson, A Blythe ^a   Eheman, Christie R ^a   Altekruse, Sean F ^b   Ward, John W ^c   Jemal, Ahmedin ^d   Sherman, Recinda L ^e   Henley, S Jane ^a   Holtzman, Deborah ^c   Lake, Andrew ^f   Noone, Anne Michelle ^b   Anderson, Robert N ^g   Ma, Jiemin ^d   Ly, Kathleen N ^c   Cronin, Kathleen A ^b   Penberthy, Lynne ^b   Kohler, Betsy A ^e  

^a NATIONAL CENTER FOR CHRONIC DISEASE PREVENTION AND HEALTH PROMOTION   (United States)

^b NATIONAL CANCER INSTITUTE   (United States)

^c CENTERS FOR DISEASE CONTROL AND PREVENTION   (United States)

^d AMERICAN CANCER SOCIETY   (United States)

^e North American Association of Central Cancer Registries   (United States)

^f INFORMATION MANAGEMENT SERVICES INC   (United States)

^g NATIONAL CENTER FOR HEALTH STATISTICS   (United States)

Author keywords

and End Results (SEER); cancer; Epidemiology; incidence; liver cancer; mortality; National Program of Cancer Registries (NPCR); North American Association of Central Cancer Registries (NAACCR); Surveillance; survival; trends; viral hepatitis

Indexed keywords

ADOLESCENT; ADULT; AFRICAN AMERICAN; AGED; ALASKA NATIVE; ANCESTRY GROUP; ASIAN; BLADDER CANCER; BRAIN CANCER; BREAST CANCER; BRONCHUS CANCER; CANCER INCIDENCE; CANCER MORTALITY; CANCER REGISTRY; CAUCASIAN; CHILD; COHORT ANALYSIS; COLORECTAL CANCER; ESOPHAGUS CANCER; ETHNIC GROUP; FEMALE; HEART CANCER; HEPATITIS C VIRUS; HISPANIC; HUMAN; KIDNEY CANCER; LARYNX CANCER; LEUKEMIA; LIVER CANCER; LUNG CANCER; MALE; MELANOMA; MORTALITY RATE; MOUTH CANCER; MYELOMA; NATIONAL HEALTH ORGANIZATION; NONHODGKIN LYMPHOMA; OVARY CANCER; PACIFIC ISLANDER; PANCREAS CANCER; PHARYNX CANCER; PRIORITY JOURNAL; PROSTATE CANCER; PUBLIC HEALTH SERVICE; REVIEW; SOFT TISSUE CANCER; STOMACH CANCER; THYROID CANCER; TREND STUDY; UTERINE CERVIX CANCER; UTERUS CANCER; AGE DISTRIBUTION; CAUSE OF DEATH; ETHNOLOGY; INCIDENCE; LIVER NEOPLASMS; NEOPLASMS; NON PROFIT ORGANIZATION; REGISTER; SEX DIFFERENCE; SEX RATIO; STATISTICS AND NUMERICAL DATA; TIME FACTOR; TRENDS; UNITED STATES;

AGE DISTRIBUTION; AMERICAN CANCER SOCIETY; CAUSE OF DEATH; CENTERS FOR DISEASE CONTROL AND PREVENTION (U.S.); CONTINENTAL POPULATION GROUPS; ETHNIC GROUPS; FEMALE; HUMANS; INCIDENCE; LIVER NEOPLASMS; MALE; NATIONAL CANCER INSTITUTE (U.S.); NEOPLASMS; REGISTRIES; SEX DISTRIBUTION; SEX FACTORS; TIME FACTORS; UNITED STATES;

EID: 84960153686     PISSN: 0008543X     EISSN: 10970142     Source Type: Journal    
DOI: 10.1002/cncr.29936     Document Type: Review

References (125)

1. Wingo PA, Ries LA, Rosenberg HM, Miller DS, Edwards BK,. Cancer incidence and mortality, 1973-1995: a report card for the United States. Cancer. 1998; 82: 1197-1207.
2. Wingo PA, Ries LA, Giovino GA, et al., Annual report to the nation on the status of cancer, 1973-1996, with a special section on lung cancer and tobacco smoking. J Natl Cancer Inst. 1999; 91: 675-690.
3. Ries LA, Wingo PA, Miller DS, et al., The annual report to the nation on the status of cancer, 1973-1997, with a special section on colorectal cancer. Cancer. 2000; 88: 2398-23424.
4. Howe HL, Wingo PA, Thun MJ, et al., Annual report to the nation on the status of cancer (1973 through 1998), featuring cancers with recent increasing trends. J Natl Cancer Inst. 2001; 93: 824-842.
5. Edwards BK, Howe HL, Ries LA, et al., Annual report to the nation on the status of cancer, 1973-1999, featuring implications of age and aging on US cancer burden. Cancer. 2002; 94: 2766-2792.
6. Weir HK, Thun MJ, Hankey BF, et al., Annual report to the nation on the status of cancer, 1975-2000, featuring the uses of surveillance data for cancer prevention and control. J Natl Cancer Inst. 2003; 95: 1276-1299.
7. Jemal A, Clegg LX, Ward E, et al., Annual report to the nation on the status of cancer, 1975-2001, with a special feature regarding survival. Cancer. 2004; 101: 3-27.
8. Edwards BK, Brown ML, Wingo PA, et al., Annual report to the nation on the status of cancer, 1975-2002, featuring population-based trends in cancer treatment. J Natl Cancer Inst. 2005; 97: 1407-1427.
9. Howe HL, Wu X, Ries LA, et al., Annual report to the nation on the status of cancer, 1975-2003, featuring cancer among US Hispanic/Latino populations. Cancer. 2006; 107: 1711-1742.
10. Espey DK, Wu XC, Swan J, et al., Annual report to the nation on the status of cancer, 1975-2004, featuring cancer in American Indians and Alaska Natives. Cancer. 2007; 110: 2119-2152.
11. Jemal A, Thun MJ, Ries LA, et al., Annual report to the nation on the status of cancer, 1975-2005, featuring trends in lung cancer, tobacco use, and tobacco control. J Natl Cancer Inst. 2008; 100: 1672-1694.
12. Edwards BK, Ward E, Kohler BA, et al., Annual report to the nation on the status of cancer, 1975-2006, featuring colorectal cancer trends and impact of interventions (risk factors, screening, and treatment) to reduce future rates. Cancer. 2010; 116: 544-573.
13. Kohler BA, Ward E, McCarthy BJ, et al., Annual report to the nation on the status of cancer, 1975-2007, featuring tumors of the brain and other nervous system. J Natl Cancer Inst. 2011; 103: 714-736.
14. Eheman C, Henley SJ, Ballard-Barbash R, et al., Annual report to the nation on the status of cancer, 1975-2008, featuring cancers associated with excess weight and lack of sufficient physical activity. Cancer. 2012; 118: 2338-2366.
15. Jemal A, Simard EP, Dorell C, et al., Annual report to the nation on the status of cancer, 1975-2009, featuring the burden and trends in human papillomavirus (HPV)-associated cancers and HPV vaccination coverage levels. J Natl Cancer Inst. 2013; 105: 175-201.
16. Edwards BK, Noone AM, Mariotto AB, et al., Annual report to the nation on the status of cancer, 1975-2010, featuring prevalence of comorbidity and impact on survival among persons with lung, colorectal, breast, or prostate cancer. Cancer. 2014; 120: 1290-1314.
17. Kohler BA, Sherman RL, Howlader N, et al., Annual report to the nation on the status of cancer, 1975-2011, featuring incidence of breast cancer subtypes by race/ethnicity, poverty, and state [serial online]. J Natl Cancer Inst. 2015; 107: djv048.
18. Ferlay J, Soerjomataram I, Dikshit R, et al., Cancer incidence and mortality worldwide: sources, methods and major patterns in GLOBOCAN 2012 [serial online]. Int J Cancer. 2015; 136: E359-E386.
19. US Cancer Statistics Working Group. United States Cancer Statistics: 1999-2012 Incidence and Mortality Web-based Report. Atlanta, GA: US Department of Health and Human Services, Centers for Disease Control and Prevention, and National Cancer Institute; 2015. Available at: www.cdc.gov/uscs. Accessed September 2, 1015.
20. Howlader N, Noone AM, Krapcho M, et al, eds. SEER Cancer Statistics Review, 1975-2012. [Based on the November 2014 SEER data submission, posted to the SEER web site, April 2015.] Bethesda, MD: National Cancer Institute; 2014.
21. de Martel C, Maucort-Boulch D, Plummer M, Franceschi S,. World-wide relative contribution of hepatitis B and C viruses in hepatocellular carcinoma. Hepatology. 2015; 62: 1190-1200.
22. Di Bisceglie AM, Lyra AC, Schwartz M, et al., Hepatitis C-related hepatocellular carcinoma in the United States: influence of ethnic status. Am J Gastroenterol. 2003; 98: 2060-2063.
23. El-Serag HB,. Epidemiology of hepatocellular carcinoma in USA. Hepatol Res. 2007; 37 (suppl 2): S88-S94.
24. Kowdley KV, Wang CC, Welch S, Roberts H, Brosgart CL,. Prevalence of chronic hepatitis B among foreign-born persons living in the United States by country of origin. Hepatology. 2012; 56: 422-433.
25. Roberts H, Kruszon-Moran D, Ly KN, et al., Prevalence of chronic hepatitis B virus (HBV) infection in US households-National Health and Nutrition Examination Survey (NHANES), 1988-2012. Hepatology. 2016; 63: 388-397.
26. Denniston MM, Jiles RB, Drobeniuc J, et al., Chronic hepatitis C virus infection in the United States, National Health and Nutrition Examination Survey 2003 to 2010. Ann Intern Med. 2014; 160: 293-300.
27. Edlin BR, Eckhardt BJ, Shu MA, Holmberg SD, Swan T,. Towards a more accurate estimate of the prevalence of hepatitis C in the United States. Hepatology. 2015; 62: 1353-1363.
28. Armstrong GL, Wasley A, Simard EP, McQuillan GM, Kuhnert WL, Alter MJ,. The prevalence of hepatitis C virus infection in the United States, 1999 through 2002. Ann Intern Med. 2006; 144: 705-714.
29. Rein DB, Wittenborn JS, Weinbaum CM, Sabin M, Smith BD, Lesesne SB,. Forecasting the morbidity and mortality associated with prevalent cases of pre-cirrhotic chronic hepatitis C in the United States. Dig Liver Dis. 2011; 43: 66-72.
30. Moyer VA,. Screening for cervical cancer: US Preventive Services Task Force recommendation statement. Ann Intern Med. 2012; 156: 880-891.
31. Smith BD, Morgan RL, Beckett GA, et al., Recommendations for the identification of chronic hepatitis C virus infection among persons born during 1945-1965. MMWR Recomm Rep. 2012; 61 (RR-4): 1-32.
32. Welzel TM, Graubard BI, Quraishi S, et al., Population-attributable fractions of risk factors for hepatocellular carcinoma in the United States. Am J Gastroenterol. 2013; 108: 1314-1321.
33. North American Association of Central Cancer Registries (NAACCR). NAACCR Data Quality Criteria. Available at: http://www.naaccr.org/Certification/Criteria.aspx. Accessed July 8, 2015.
34. World Health Organization. International Classification of Diseases for Oncology. 3rd ed. Geneva, Switzerland; World Health Organization Press; 2000.
35. Espey DK, Jim MA, Richards TB, Begay C, Haverkamp D, Roberts D,. Methods for improving the quality and completeness of mortality data for American Indians and Alaska Natives. Am J Public Health. 2014; 104 (suppl 3): S286-S294.
36. Espey DK, Wiggins CL, Jim MA, Miller BA, Johnson CJ, Becker TM,. Methods for improving cancer surveillance data in American Indian and Alaska Native populations. Cancer. 2008; 113 (5 suppl): 1120-1130.
37. National Cancer Institute. SEER Registry Groupings for Analyses. Available at: http://seer.cancer.gov/registries/terms.html. Accessed July 8, 2015.
38. Murphy SL, Kochanek KD, Xu J, Heron M,. Deaths: final data for 2012. Nat Vital Stat Rep. 2015; 63: 1-117.
39. Surveillance, Epidemiology, and End Results (SEER) Program; National Cancer Institute. Population estimates used in NCI's SEER∗Stat software. Available at: http://seer.cancer.gov/popdata/methods.html. Accessed July 13, 2015.
40. Ingram DD, Parker JD, Schenker N, et al., United States Census 2000 population with bridged race categories. Vital Health Stat 2. 2003; 135: 1-55.
41. World Health Organization. International Classification of Diseases, 10th Revision. Geneva, Switzerland: World Health Organization; 1998.
42. National Center for Health Statistics. Instructions for Classifying the Underlying Cause of Death, ICD-10, 2015. Available at: http://www.cdc.gov/nchs/data/dvs/2a-2015.pdf. Accessed October 20, 2015.
43. Surveillance Research Program, National Cancer Institute SEER∗Stat software (www.seer.cancer.gov/seerstat) version 8.2.1. Bethesda, MD: National Cancer Institute; 2015.
44. Tiwari RC, Clegg LX, Zou Z,. Efficient interval estimation for age-adjusted cancer rates. Stat Methods Med Res. 2006; 15: 547-569.
45. National Cancer Institute. Joinpoint Regression Program, Version 4.2.0.2 (June 2015). Bethesda, MD: National Cancer Institute; 2015. Available at: http://surveillance.cancer.gov/joinpoint/. Accessed July 14, 2015.
46. Kim HJ, Fay MP, Feuer EJ, Midthune DN,. Permutation tests for joinpoint regression with applications to cancer rates. Stat Med. 2000; 19: 335-351.
47. Clegg LX, Hankey BF, Tiwari R, Feuer EJ, Edwards BK,. Estimating average annual per cent change in trend analysis. Stat Med. 2009; 28: 3670-3682.
48. Clegg LX, Feuer EJ, Midthune DN, Fay MP, Hankey BF,. Impact of reporting delay and reporting error on cancer incidence rates and trends. J Natl Cancer Inst. 2002; 94: 1537-1545.
49. Rosenberg PS, Check DP, Anderson WF,. A web tool for age-period-cohort analysis of cancer incidence and mortality rates. Cancer Epidemiol Biomarkers Prev. 2014; 23: 2296-2302.
50. Chu KC, Miller BA, Feuer EJ, Hankey BF,. A method for partitioning cancer mortality trends by factors associated with diagnosis: an application to female breast cancer. J Clin Epidemiol. 1994; 47: 1451-1461.
51. National Cancer Institute. Cancer Trends Progress Report. Person-Years of Life Lost. Bethesda, MD: National Cancer Institute; 2015. Available at: http://www.progressreport.cancer.gov/end/life-lost. Accessed October 22, 2015.
52. Arias E,. United States life tables, 2010. Natl Vital Stat Rep. 2014; 63: 1-63.
53. Ly KN, Xing J, Klevens RM, Jiles RB, Ward JW, Holmberg SD,. The increasing burden of mortality from viral hepatitis in the United States between 1999 and 2007. Ann Intern Med. 2012; 156: 271-278.
54. Centers for Disease Control and Prevention (CDC). State-specific trends in lung cancer incidence and smoking-United States, 1999-2008. MMWR Morb Mortal Wkly Rep. 2011; 60: 1243-1247.
55. Centers for Disease Control and Prevention (CDC). Vital signs: current cigarette smoking among adults aged ≥18 years with mental illness-United States, 2009-2011. MMWR Morb Mortal Wkly Rep. 2013; 62: 81-87.
56. Henley SJ, Richards TB, Underwood JM, Eheman CR, Plescia M, McAfee TA,. Lung cancer incidence trends among men and women-United States, 2005-2009. MMWR Morb Mortal Wkly Rep. 2014; 63: 1-5.
57. Moyer VA,. Screening for lung cancer: US Preventive Services Task Force recommendation statement. Ann Intern Med. 2014; 160: 330-338.
58. Zauber AG, Lansdorp-Vogelaar I, Knudsen AB, Wilschut J, van Ballegooijen M, Kuntz KM,. Evaluating test strategies for colorectal cancer screening: a decision analysis for the US Preventive Services Task Force. Ann Intern Med. 2008; 149: 659-669.
59. Levin B, Lieberman DA, McFarland B, et al., Screening and surveillance for the early detection of colorectal cancer and adenomatous polyps, 2008: a joint guideline from the American Cancer Society, the US Multi-Society Task Force on Colorectal Cancer, and the American College of Radiology. Gastroenterology. 2008; 134: 1570-1595.
60. Littlejohn C, Hilton S, Macfarlane GJ, Phull P,. Systematic review and meta-analysis of the evidence for flexible sigmoidoscopy as a screening method for the prevention of colorectal cancer. Br J Surg. 2012; 99: 1488-1500.
61. Nishihara R, Wu K, Lochhead P, et al., Long-term colorectal-cancer incidence and mortality after lower endoscopy. N Engl J Med. 2013; 369: 1095-1105.
62. Centers for Disease Control and Prevention (CDC). Vital signs: colorectal cancer screening test use-United States, 2012. MMWR Morb Mortal Wkly Rep. 2013; 62: 881-888.
63. Centers for Disease Control and Prevention (CDC). CDC's Colorectal Cancer Control Program. About the Program. Available at: http://www.cdc.gov/cancer/crccp/about.htm. Accessed September 23, 2015.
64. National Colorectal Cancer Roundtable. About the Roundtable. Available at: http://nccrt.org/about/. Accessed September 23, 2015.
65. Berry DA, Cronin KA, Plevritis SK, et al., Effect of screening and adjuvant therapy on mortality from breast cancer. N Engl J Med. 2005; 353: 1784-1792.
66. Centers for Disease Control and Prevention (CDC). CDC's National Breast and Cervical Cancer Early Detection Program. About the Program. Available at: http://www.cdc.gov/cancer/nbccedp/about.htm. Accessed September 23, 2015.
67. Howard DH, Tangka FK, Guy GP, Ekwueme DU, Lipscomb J,. Prostate cancer screening in men ages 75 and older fell by 8 percentage points after task force recommendation. Health Aff (Millwood). 2013; 32: 596-602.
68. Barocas DA, Mallin K, Graves AJ, et al., Effect of the USPSTF grade D recommendation against screening for prostate cancer on incident prostate cancer diagnoses in the United States. J Urol. 2015; 194: 1587-1593.
69. Drazer MW, Huo D, Eggener SE,. National prostate cancer screening rates after the 2012 US Preventive Services Task Force recommendation discouraging prostate-specific antigen-based screening. J Clin Oncol. 2015; 33: 2416-2423.
70. Li J, Berkowitz Z, Hall IJ,. Decrease in prostate cancer testing following the US Preventive Services Task Force (USPSTF) recommendations. J Am Board Fam Med. 2015; 28: 491-493.
71. US Preventive Services Task Force. Screening for prostate cancer: US Preventive Services Task Force recommendation statement. Ann Intern Med. 2008; 149: 185-191.
72. Jemal A, Fedewa SA, Ma J, et al., Prostate cancer incidence and PSA testing patterns in relation to USPSTF screening recommendations. JAMA. 2015; 314: 2054-2061.
73. El-Serag HB,. Epidemiology of viral hepatitis and hepatocellular carcinoma [serial online]. Gastroenterology. 2012; 142: 1264-1273.e1.
74. Ly KN, Xing J, Klevens RM, Jiles RB, Holmberg SD,. Causes of death and characteristics of decedents with viral hepatitis, United States, 2010. Clin Infect Dis. 2014; 58: 40-49.
75. Wise M, Bialek S, Finelli L, Bell BP, Sorvillo F,. Changing trends in hepatitis C-related mortality in the United States, 1995-2004. Hepatology. 2008; 47: 1128-1135.
76. Moyer VA,. Screening for hepatitis C virus infection in adults: US Preventive Services Task Force recommendation statement. Ann Intern Med. 2013; 159: 349-357.
77. Jemal A, Fedewa SA,. Prevalence of hepatitis C virus testing in cohorts born between 1945 and 1965 in the US [letter]. Am J Prev Med. 2015; 48: e7-e9.
78. McQuillan GM, Kruszon-Moran D, Kottiri BJ, Curtin LR, Lucas JW, Kington RS,. Racial and ethnic differences in the seroprevalence of 6 infectious diseases in the United States: data from NHANES III, 1988-1994. Am J Public Health. 2004; 94: 1952-1958.
79. Centers for Disease Control and Prevention (CDC). Screening for chronic hepatitis B among Asian/Pacific Islander populations-New York City, 2005. MMWR Morb Mortal Wkly Rep. 2006; 55: 505-509.
80. World Health Organization. Immunization Coverage Fact Sheet. Geneva, Switzerland: World Health Organization; 2015. Available at: http://www.who.int/mediacentre/factsheets/fs378/en/. Accessed September 3, 2015.
81. World Health Organization. WHO Vaccine-Preventable Diseases: Monitoring System. 2015 Global Summary. Geneva, Switzerland: World Health Organization; 2015. Available at: http://apps.who.int/immunization-monitoring/globalsummary/. Accessed September 3, 2015.
82. World Health Organization. Global Status Report on Noncommunicable Diseases 2010. Geneva, Switzerland: World Health Organization; 2011. Available at: http://www.who.int/nmh/publications/ncd-report-full-en.pdf. Accessed October 20, 2015.
83. Liang X, Bi S, Yang W, et al., Reprint of: Epidemiological serosurvey of hepatitis B in China-declining HBV prevalence due to hepatitis B vaccination. Vaccine. 2013; 31 (suppl 9): J21-J28.
84. Gordon SC, Lamerato LE, Rupp LB, et al., Antiviral therapy for chronic hepatitis B virus infection and development of hepatocellular carcinoma in a US population. Clin Gastroenterol Hepatol. 2014; 12: 885-893.
85. Lai CL, Yuen MF,. Prevention of hepatitis B virus-related hepatocellular carcinoma with antiviral therapy. Hepatology. 2013; 57: 399-408.
86. LeFevre ML,. Screening for hepatitis B virus infection in nonpregnant adolescents and adults: US Preventive Services Task Force recommendation statement. Ann Intern Med. 2014; 161: 58-66.
87. McGlynn KA, London WT,. The global epidemiology of hepatocellular carcinoma: present and future. Clin Liver Dis. 2011; 15: 223-243.
88. Chhatwal J, Kanwal F, Roberts MS, Dunn MA,. Cost-effectiveness and budget impact of hepatitis C virus treatment with sofosbuvir and ledipasvir in the United States. Ann Intern Med. 2015; 162: 397-406.
89. Drenth JP,. HCV treatment-no more room for interferonologists? N Engl J Med. 2013; 368: 1931-1932.
90. American Association for the Study of Liver Diseases and the Infectious Diseases Society of America. HCV Guidance: Recommendations for Testing, Managing, and Treating Hepatitis C. 2015. Available at: http://www.hcvguidelines.org. Accessed November 2, 2015.
91. Afdhal N, Reddy KR, Nelson DR, et al., Ledipasvir and sofosbuvir for previously treated HCV genotype 1 infection. N Engl J Med. 2014; 370: 1483-1493.
92. Lawitz E, Mangia A, Wyles D, et al., Sofosbuvir for previously untreated chronic hepatitis C infection. N Engl J Med. 2013; 368: 1878-1887.
93. Denniston MM, Klevens RM, McQuillan GM, Jiles RB,. Awareness of infection, knowledge of hepatitis C, and medical follow-up among individuals testing positive for hepatitis C: National Health and Nutrition Examination Survey 2001-2008. Hepatology. 2012; 55: 1652-1661.
94. Rein DB, Wittenborn JS, Smith BD, Liffmann DK, Ward JW,. The cost-effectiveness, health benefits, and financial costs of new antiviral treatments for hepatitis C virus. Clin Infect Dis. 2015; 61: 157-168.
95. Ward JW, Mermin JH,. Simple, effective, but out of reach? Public health implications of HCV drugs. N Engl J Med. 2015; 373: 2678-2680.
96. Liebler CA, Halpern-Manners A,. A practical approach to using multiple-race response data: a bridging method for public-use microdata. Demography. 2008; 45: 143-155.
97. Henry KA, Sherman RL, McDonald K, et al., Associations of census-tract poverty with subsite-specific colorectal cancer incidence rates and stage of disease at diagnosis in the United States [serial online]. J Cancer Epidemiol. 2014; 2014: 823484.
98. Pinheiro PS, Sherman RL, Trapido EJ, et al., Cancer incidence in first generation US Hispanics: Cubans, Mexicans, Puerto Ricans, and new Latinos. Cancer Epidemiol Biomarkers Prev. 2009; 18: 2162-2169.
99. Pinheiro PS, Sherman RL,. Why an alternative algorithm for identification of Hispanic subgroups is useful. J Registry Manag. 2009; 36: 3-4.
100. Arias E, Schauman WS, Eschbach K, Sorlie PD, Backlund E,. The validity of race and Hispanic origin reporting on death certificates in the United States. Vital Health Stat 2. 2008; 148: 1-23.
101. Hahn RA, Wetterhall SF, Gay GA, et al., The recording of demographic information on death certificates: a national survey of funeral directors. Public Health Rep. 2002; 117: 37-43.
102. Murray CJ, Rajaratnam JK, Marcus J, Laakso T, Lopez AD,. What can we conclude from death registration? Improved methods for evaluating completeness [serial online]. PLoS Med. 2010; 7: e1000262.
103. Adih WK, Selik RM, Hu X,. Trends in diseases reported on US death certificates that mentioned HIV infection, 1996-2006. J Int Assoc Physicians AIDS Care (Chic). 2011; 10: 5-11.
104. Centers for Disease Control and Prevention (CDC). Hepatocellular carcinoma-United States, 2001-2006. MMWR Morb Mortal Wkly Rep. 2010; 59: 517-520.
105. Daniels D, Grytdal S, Wasley A,. Surveillance for acute viral hepatitis-United States, 2007. MMWR Surveill Summ. 2009; 58: 1-27.
106. Morgan RL, Baack B, Smith BD, Yartel A, Pitasi M, Falck-Ytter Y,. Eradication of hepatitis C virus infection and the development of hepatocellular carcinoma: a meta-analysis of observational studies. Ann Intern Med. 2013; 158 (5 pt 1): 329-337.
107. van der Meer AJ, Veldt BJ, Feld JJ, et al., Association between sustained virological response and all-cause mortality among patients with chronic hepatitis C and advanced hepatic fibrosis. JAMA. 2012; 308: 2584-2593.
108. Smith BD, Smith GL, Hurria A, Hortobagyi GN, Buchholz TA,. Future of cancer incidence in the United States: burdens upon an aging, changing nation. J Clin Oncol. 2009; 27: 2758-2765.
109. National Center for Chronic Disease Prevention and Health Promotion Office on Smoking and Health. The Health Consequences of Smoking-50 Years of Progress: A Report of the Surgeon General. Atlanta, GA: Centers for Disease Control and Prevention; 2014.
110. Wiseman M,. The second World Cancer Research Fund/American Institute for Cancer Research expert report. Food, nutrition, physical activity, and the prevention of cancer: a global perspective. Proc Nutr Soc. 2008; 67: 253-256.
111. US Preventive Services Task Force. Screening for colorectal cancer: US Preventive Services Task Force recommendation statement. Ann Intern Med. 2008; 149: 627-637.
112. US Preventive Services Task Force. Screening for breast cancer: US Preventive Services Task Force recommendation statement. Ann Intern Med. 2009; 151: 716-726.
113. US Preventive Services Task Force. Recommendations for Primary Care Practice. Rockville, MD: 2014. Available at: http://www.uspreventiveservicestaskforce.org/Page/Name/recommendations. Accessed September 28, 2015.
114. Henley SJ, King JB, German RR, Richardson LC, Plescia M,. Surveillance of screening-detected cancers (colon and rectum, breast, and cervix)-United States, 2004-2006. MMWR Surveill Summ. 2010; 59: 1-25.
115. Centers for Disease Control and Prevention (CDC). A National Action Plan for Cancer Survivorship: Advancing Public Health Strategies. Atlanta, GA: CDC; 2004. Available at: http://www.cdc.gov/cancer/survivorship/pdf/plan.pdf. Accessed September 28, 2015.
116. Cancer survivors: living longer, and now, better. Lancet. 2004; 364: 2153-2154.
117. Bradley CJ, Bednarek HL, Neumark D,. Breast cancer and women's labor supply. Health Serv Res. 2002; 37: 1309-1328.
118. Sasser AC, Rousculp MD, Birnbaum HG, Oster EF, Lufkin E, Mallet D,. Economic burden of osteoporosis, breast cancer, and cardiovascular disease among postmenopausal women in an employed population. Womens Health Issues. 2005; 15: 97-108.
119. Underwood JM, Townsend JS, Stewart SL, et al., Surveillance of demographic characteristics and health behaviors among adult cancer survivors-Behavioral Risk Factor Surveillance System, United States, 2009 MMWR Surveill Summ. 2012; 61: 1-23.
120. Yabroff KR, Davis WW, Lamont EB, et al., Patient time costs associated with cancer care. J Natl Cancer Inst. 2007; 99: 14-23.
121. Yabroff KR, Lawrence WF, Clauser S, Davis WW, Brown ML,. Burden of illness in cancer survivors: findings from a population-based national sample. J Natl Cancer Inst. 2004; 96: 1322-1330.
122. Ng AK, Travis LB,. Subsequent malignant neoplasms in cancer survivors. Cancer J. 2008; 14: 429-434.
123. Sunga AY, Eberl MM, Oeffinger KC, Hudson MM, Mahoney MC,. Care of cancer survivors. Am Fam Physician. 2005; 71: 699-706.
124. Buehler JW,; Centers for Disease Control and Prevention. CDC's vision for public health surveillance in the 21st century. Introduction. MMWR Surveill Summ. 2012; 61 (suppl): 1-2.
125. Nsubuga P, White E, Thacker SB, et al., Public health surveillance: a tool for targeting and monitoring interventions. Chapter 53. In:, Jamison DT, Breman JG, Measham AR, et al, eds. World Bank Group. Disease Control Priorities for Developing Countries. 2nd ed. Washington, DC: World Bank Publishers; 2006: 997-1015.